Eli Lilly (NYSE:LLY) is scheduled to announce Q3 earnings results on Wednesday, October 30th, before market open. Analysts expect profit of $1.47 per share on revenue of $12.12B (+27.7% Y/Y).

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss. With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with ...

Warnings - Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ...

New results show Eli Lilly (NYSE: LLY) Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...

LEO Pharma Inc., a global leader in medical dermatology, will present a comprehensive catalog of new data around investigational delgocitinib cream in the treatment of adults with moderate to ...

Other systematic therapies for AD include Ebglyss (lebrikizumab), Cibinqo (abrocitinib) and Rinvoq (upadacitinib).

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...